Goldman initiated coverage on Viridian Therapeutics with a new price target
$VRDN
Medical Specialities
Health Care
Goldman initiated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $23.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/11/2024 | $30.00 → $38.00 | Buy | Needham |
| 6/11/2024 | $29.00 | Outperform | Wolfe Research |
| 6/6/2024 | $23.00 | Buy | Goldman |
| 5/9/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 5/9/2024 | $25.00 → $20.00 | Buy → Neutral | B. Riley Securities |
| 6/14/2023 | $51.00 | Outperform | Credit Suisse |
| 6/14/2023 | $46.00 | Buy | BTIG Research |
| 5/30/2023 | $44.00 | Outperform | RBC Capital Mkts |
- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December 2024 - - Initiated two global phase 3 clinical trials of subcutaneous VRDN-003, REVEAL-1 and REVEAL-2 in August, in active and chronic TED, respectively; topline data anticipated in the first half of 2026 - - New non-human primate (NHP) data for VRDN-008, a next-generation bispecific neonatal Fc receptor (FcRn) inhibitor, demonstrates a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile; Investigational New Drug (IND) submission is planned for year-end 2025 and proof
Viridian Therapeutics, Inc. (NASDAQ:VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 150,600 shares of the company's common stock to six new employees (the "Inducement Grants") on November 1, 2024 (the "Grant Date"). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to th
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering price of $18.75 per share and 20,000 shares of Series B non-voting convertible preferred stock at a public offering price of $1,250.06250 per share, which are convertible into 1,333,400 shares of common stock, subject to beneficial ownershi
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
10-Q - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
Viridian Therapeutics, Inc. (NASDAQ:VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer. "I am very pleased to welcome Jennifer to Viridian to lead our legal team and join Viridian's executive team ahead of an exciting set of milestones this year across our thyroid eye disease and anti-neonatal Fc receptor portfolios," said Steve Mahoney, Viridian President and Chief Executive Officer. "With Jennifer's deep expertise and long history in public biotech companies advising on a broad set o
– Stephen Mahoney appointed President and Chief Executive Officer – – Potential best-in-class subcutaneous and intravenous thyroid eye disease (TED) programs targeting insulin-like growth factor 1 receptor (IGF-1R) remain on track; subcutaneous program selection expected by year-end 2023 and VRDN-001 THRIVE Phase 3 topline results in active TED expected in mid-2024 – – Company discloses novel portfolio of preclinical neonatal Fc receptor (FcRn) inhibitors with broad potential to treat autoimmune diseases; first Investigational New Drug (IND) submission planned by year end 2024 – – Private placement with participation from new and existing investors to fund portfolio strategy and exten
WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO). The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization. Mr. Casciano, who most recently served as Chief Executive Officer (CEO) and member of the board of directors of Teal Bio, brings to Viridian more than two decades of sales, marketing, and commercial leadership experience in the biopharma industry. "Tony's arr
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
Needham reiterated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $38.00 from $30.00 previously
Wolfe Research initiated coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $29.00
Goldman initiated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $23.00
- THRIVE-2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites -- THRIVE topline readout in patients with active TED on track for September 2024 -- THRIVE-2 topline readout on track for year-end 2024 -Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in THRIVE-2, its phase 3 clinical trial for VRDN-001 in patients with chronic TED.THRIVE-2 enrolled 188 patients globally and exceeded the enrollment target of 159 patients due to patient demand. Approximately 40% of the enr
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Viridian Therapeutics (NASDAQ:VRDN) in the last three months. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 2 1 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $26.86, along with a high e
HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 price target.
- Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r
- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (TED) - - Conference call and webcast to be held Tuesday, September 10, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, will host a conference call and webcast to report topline data for the THRIVE phase 3 clinical trial, evaluating VRDN-001 in patients with active TED, on Tuesday, September 10, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presentations" on the In
- THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track for topline readout by year-end 2024 - - Positive VRDN-003 Type C meeting held with the US Food and Drug Administration (FDA); pivotal program on track to start mid-year 2024 - - VRDN-006 FcRn inhibitor remains on track for Investigational New Drug (IND) submission by year-end 2024; non-human primate data expected for VRDN-008, a half-life extended FcRn inhibitor, in the second half of 2024 - - Con